奥氮平治疗脑器质性疾病所致精神障碍的临床效果与安全性分析

摘要

Objective To observe the clinical efficacy and safety of olanzapine in the treatment of mental disorders caused by brain organic diseases.Methods Eighty-one patients with mental disorder caused by brain organic disease were enrolled in the study and randomly divided into the control group(39 cases)and the experimental group(42 cases).The control group was treated with risperidone tablets and the experimental group was treated with olanzapine tablets,the patients in the two groups were treated for 4 weeks.After 4 weeks, the clinical efficacy,the scores of BPRS and the adverse reactions in the treatment were observed.Results The total efficiency of the control group 66.7%(26/39),the total efficiency of experimental group was 92.8%(39/42),there was significant difference in total efficiency between the two groups(χ2=7.889,P<0.05).Before the treatment,BRPS scores in the two groups were(51.42±6.38)points and(50.32±7.15)points,respectively, After 4 weeks of treatment,BRPS scores were(39.21 ± 7.43)points and(30.10 ± 3.88)points in the two groups,the differences in BPRS score in the two groups before treatment and at 4 weeks after treatment were statistically significant(control group: t=7.845,P=0.003,experimental group: t=8.321,P=0.002),there was significant difference between the control group and the experimental group in BPRS score(t=6.773,P=0.003).The incidence rate of body mass increase in the experimental group was 40.5%(17/42),significantly higher than that of the control group(15.4%)(6/39),the difference was statistically significant(χ2=6.576,P<0.05),while the incidence rates of myotonia and tremor adverse reaction were 16.7%(7/42)and 19.0%(8/42),significantly lower than those in the control group 35.9%(14/39)and 38.5%(15/39),the differences were statistically significant(myotonia:χ2=5.187,P<0.05;tremor; χ2=4.433,P<0.05).Adverse drug reactions can be effectively alleviated after symptomatic treatment.Conclusion Olanzapine has good clinical efficacy and safety and low adverse reactions in the treatment of mental disorders caused by organic brain disease.%目的 观察奥氮平治疗脑器质性疾病所致精神障碍的临床效果与安全性.方法 81例脑器质性疾病所致的精神障碍患者随机分为对照组39例、实验组42例.对照组口服利培酮片治疗,实验组口服奥氮平片治疗,两组患者连续用药4周.4周后观察患者的临床疗效,以及治疗后应用简明精神病症状评分量表(BPRS)评分以及治疗中的不良反应.结果 对照组总有效率66.7%(26/39),实验组总有效率92.8%(39/42),两组治疗总有效率比较差异有统计学意义χ2=7.889,P<0.05;对照组与实验组治疗前BRPS评分分别为(51.42± 6.38)分、(50.32± 7.15)分,治疗4周后BRPS评分分别为(39.21 ±7.43)分、(30.10±3.88)分,两组BPRS评分在治疗前和治疗4周时比较差异有统计学意义(对照组t=7.845,P=0.003,实验组t=8.321,P=0.002),实验组与对照组比较,差异有统计学意义(t=6.773,P=0.003).实验组体质量增加的发生率为40.5%(17/42)明显高于对照组15.4%(6/39),差异有统计学意义(χ2=6.576,P<0.05),而其肌强直和震颤的不良反应发生率为16.7%(7/42)和19.0%(8/42)明显低于对照组的35.9%(14/39)和38.5%(15/39),差异有统计学意义(肌强直χ2=5.187,P<0.05;震颤χ2=4.433,P<0.05).不良反应经过对症支持治疗后均可以有效缓解.结论 奥氮平治疗脑器质性疾病所致的精神障碍具有较好的临床效果和安全性,且不良反应发生率低.